What are the first-line treatments for PCOS?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
First-line treatment for PCOS depends on the goal. Lifestyle intervention is recommended for everyone. For irregular cycles and hirsutism, the combined oral contraceptive pill is first line. For metabolic features, metformin. For fertility, letrozole. Anti-androgens such as spironolactone are added second, and only alongside effective contraception.
PCOS has no single first-line treatment, because treatment is chosen by target. The 2023 International Evidence-based Guideline sets four separate first-line answers: lifestyle intervention for everyone, the combined oral contraceptive pill for irregular cycles and hirsutism, metformin for metabolic features, and letrozole for ovulation induction when pregnancy is the goal. Choosing the wrong one for your target is the commonest reason PCOS treatment feels like it is not working.
Lifestyle as the base layer
The guideline recommends lifestyle intervention, meaning exercise alone or a diet combined with exercise and behavioural strategies, for all women with PCOS. It also states plainly that no single diet or exercise regimen has been shown to be superior in PCOS. That is a useful sentence to remember when a programme claims a specific PCOS diet. The focus is on overall health, prevention of weight gain, and where relevant weight management, over a timescale of months.
The pill for cycles and androgen symptoms
The combined oral contraceptive pill is the first-line medication for hirsutism and irregular menstrual cycles in reproductive age adults with PCOS. The guideline states that no specific preparation is clearly superior and that lower dose options are preferred. It works by suppressing ovarian androgen production and raising sex hormone binding globulin, and the progestin component protects the endometrium against the hyperplasia risk that comes with long gaps between periods.
Metformin, letrozole and anti-androgens
Metformin is recommended primarily for metabolic features in adults with PCOS and a BMI of 25 kg/m2 or above. Letrozole is the first-line pharmacological treatment for ovulation induction in anovulatory infertility with no other infertility factor. Anti-androgens including spironolactone have a limited, second-line role: the guideline positions them for hirsutism after at least six months of the pill or cosmetic therapy has given a suboptimal response, and only in combination with effective contraception.
| Your goal | First line | Added if response is inadequate |
|---|---|---|
| Regular cycles, endometrial protection | Combined oral contraceptive pill | Cyclical progestin if oestrogen is not an option |
| Excess hair, acne | Combined pill plus cosmetic or laser therapy | Spironolactone, with contraception |
| Glucose, lipids, weight | Lifestyle plus metformin at BMI 25 or above | Anti-obesity medication as per general guidelines |
| Pregnancy | Letrozole | Clomiphene, gonadotrophins, then IVF |
Before starting anything, write down the one or two outcomes that matter most to you this year. Bring that list to the appointment. A plan for cycles and a plan for fertility look different, and the same patient often needs them in sequence rather than together.
The clinical detail
2023 guideline positions in brief. Combined oral contraceptive pill: could be recommended in reproductive age adults with PCOS for hirsutism and/or irregular cycles, and could be considered in adolescents at risk of or diagnosed with PCOS. No preparation shown superior; lower dose preferred; 35 microgram ethinylestradiol plus cyproterone acetate is not first line given venous thromboembolism and other risks.
Metformin plus the pill: little additional clinical benefit over either alone at BMI 30 kg/m2 or below, but potentially most useful in higher metabolic risk groups including BMI above 30, impaired glucose tolerance, or high risk ethnic groups. Anti-androgens: added after a minimum of six months of pill or cosmetic therapy with suboptimal response, in combination with effective contraception, with counselling on undervirilisation of a male fetus.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine
- Polycystic Ovary Syndrome. MedlinePlus, National Library of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.